ClaireBakerMD

Endocrinology • Omaha, NE

Diabetes, Lipid Metabolism

Endocrinologist

Join to view full profile

Dr. Baker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baker's full profile

Already have an account?

Office
7831 Chicago Ct
Omaha, NE 68114
Phone+1 402-354-1230

Fax+1 402-354-1235

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Endocrinology, Diabetes, and Metabolism, 2001 - 2004
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2001
Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1998 - 1999
University of Nebraska College of MedicineClass of 1998
Nebraska Wesleyan UniversityBS, Biopsychology with Highest Distinction, 1990 - 1994

Certifications & Licensure

NE State Medical License 2004 - 2026
MN State Medical License 2001 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2012-2013
American Medical Women’s Association Memorial Achievement Citation 1998
Alpha Omega Alpha 1997
Regent’s Scholarship 1994, 1996, 1997
Department of Medicine Outstanding Student Award 1997
Hershel H. and Zelda C. Freedman Endowed Scholarship 1995
Priscilla Chain Beck Memorial Scholarship 1995
Dean’s List 1990, 1994
Phi Kappa Phi Gold Key Award First in Graduating Class, 1994
Phi Kappa Phi Fellowship 1994
Board of Governors’ Scholarship 1990, 1994
Phi Kappa Phi Honor Society 1993
Cardinal Key Honor Society 1992
Psi Chi Psychology Honorary Society 1992
Beta Beta Beta Biology Honorary Society 1992
First Place Academic Award 1990, 1991
National Merit Scholarship 1990
Most Compassionate Doctor American Registry
Fellow (FACE) American Association of Clinical Endocrinology
Join now to see all

Clinical Trials

Genetic Study in Patients With Stage II or Stage III Colon Cancer Start of enrollment: 1999 Feb 01
Completed
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma Start of enrollment: 2000 Jul 04
Completed
Phase 2
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy Start of enrollment: 1999 Sep 01
Completed
Phase 3
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Start of enrollment: 2000 Jul 12
Completed
Phase 2
Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer Start of enrollment: 2000 Dec 18
Completed
Phase 3
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer Start of enrollment: 2001 May 01
Completed
Phase 3
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer Start of enrollment: 2001 Jun 01
Completed
Phase 3
Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer Start of enrollment: 2002 Jul 01
Completed
Phase 3
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 3
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Start of enrollment: 2004 Feb 01
Completed
Phase 3
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer Start of enrollment: 2004 May 01
Completed
Phase 3
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Start of enrollment: 2008 Apr 01
Terminated
Phase 3
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Start of enrollment: 2006 Apr 24
Completed
Phase 3
A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port Start of enrollment: 2006 Oct 01
Completed
Not Applicable
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2007 Nov 01
Completed
Phase 3
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Start of enrollment: 2011 Aug 16
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

129 citations
Nitric oxide is a volume transmitter regulating postsynaptic excitability at a glutamatergic synapse.
Joern R. Steinert, Cornelia Kopp-Scheinpflug, Claire A. Baker, R. A. John Challiss, Raj Mistry
Neuron. 2008-11-26
27 citations
The sodium-iodide symporter.
Claire H. Baker, John C. Morris
Current Drug Targets. Immune, Endocrine and Metabolic Disorders. 2004-08-31
38 citations
Comparison of ultrasound-guided fine-needle aspiration biopsy with core-needle biopsy in the evaluation of thyroid nodules.
Teck Kim Khoo, Claire H. Baker, Julie Hallanger-Johnson, Andrea Tom, Clive S. Grant
Endocrine Practice. 2008-05-01

Journal Articles

Acute Pancreatitis Secondary to Primary Hyperparathyroidism in a Teenager.
Laguna LE, Schwartz MJ, van Heerden JA, Baker CH, Contemporary Surgery
A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
Cengic N, Baker CH, Schütz M, Göke B, Morris JC, Spitzweg C, Journal of Clinical Endocrinology and Metabolism
Radiodiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer.
Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER, Vile R, Göke B, Morris JC, Spitzweg C, Gene Therapy
Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
Spitzweg C, Baker CH, Bergert ER, O’Connor MK, Morris JC, Human Gene Therapy
A study assessing an injection port for administration of insulin.
Blevins T, Schwartz SL, Bode B, Aronoff S, Baker C, Kimball KT, Harrist RB, Donnelly C, Burns LC, Wooldridge AM, Diabetes Care
The Sodium-Iodide Symporter.
Baker CH, Morris JC, Current Drug Targets: Immune, Endocrine & Metabolic Disorders
Join now to see all

Abstracts/Posters

A Case of Malignant Struma Ovarii.
Baker CH, Gharib H, 5th Mayo Clinic Endocrine Course, Grand Bahama Island, Bahamas
A Case of Primary Hyperparathyroidism Associated with Nephrocalcinosis, Brown Tumors, and Pancreatitis in an Adolescent.
Baker CH, Laguna LE, Schwartz MJ, Casey MB, van Heerden JA, Rizza RA, The American Association of Clinical Endocrinologists 11th Annual Meeting, Chicago, Illinois
The Mayo Clinic Experience with Pituitary Incidentaloma.
Baker CH, Erickson BJ, Young WF, Vella A, The Endocrine Society’s 85th Annual Meeting, Philadelphia, Pennsylvania
In Vitro Induction of Radioiodine uptake in Medullary Thyroid Cancer Cells Following CMV-Promoter Driven Expression of the Sodium-Iodide Symporter.
Baker CH, Bergert ER, Morris JC, The Endocrine Society’s 85th Annual Meeting, Philadelphia, Pennsylvania
In Vitro Induction of Radio-iodine uptake in Medullary Thyroid Cancer Cells Following CEA and Calcitonin Promoter Driven Expression of the Sodium-Iodide Symporter.
Baker CH, Spitzweg C, Bergert ER, Morris JC, The Thyroid Association’s 75th Annual Meeting, Palm Beach, Florida
Radioiodine therapy of medullary thyroid cancer following calcitonin promoter-driven expression of the sodium iodide symporter.
Cengic N, Baker CH, Scholz I, Bergert ER, Goke B, Morris JC, Spitzweg C, The Thyroid Association’s 75th Annual Meeting, Palm Beach, Florida
Familial paraganglioma and gastric stromal sarcoma syndrome recognized prospectively.
Baker CH, Chun YS, Young WF, Carney, JA, The Endocrine Society’s 86th Annual Meeting, New Orleans, Louisiana
In vivo induction of radio-iodine uptake in medullary thyroid cancer cells after CEA promoter driven expression of the sodium iodide symporter.
Baker CH, Spitzweg C, Bergert ER, Morris JC, The Endocrine Society’s 86th Annual Meeting, New Orleans, Louisiana
Join now to see all

Lectures

The effects of liraglutide versus placebo when added to basal insulin analogues with or without meformin in subjects with type 2 diabetes.
Novo Nordisk Pharmaceuticals
A randomized, multicenter, double-blind, parallel, placeblo-controlled study of the effects of JNJ-28431754 on cardiovascular outcomes in adult subjects with type 2 di...
Johnson & Johnson Pharmaceutical Research & Development
Comparison of glycemice control in obese subjects with diabetes using the BD Ultra-Fine Nano 4mmx32G pen needle, and either the BD Ultra Fine Short 8mmx31G pen needle ...
BD Medical – Diabetes Care
A 26-week trial investigating the dosing flexibility, efficacy and safety of NN1250 in subjects with type 1 diabetes.
Novo Nordisk Pharmaceuticals
A trial assessing the implications of switching from insulin glargine to insulin degludec in subjects with type 2 diabetes mellitus.
Novo Nordisk Pharmaceuticals
A 52-week randomised, controlled, open label, multicenter, multinantional treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both adminis...
Novo Nordisk Pharmaceuticals
A multicenter, randomized, open-label, active-controlled study to compare the efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin glargine.
F. Hoffmann-La Roche LTD
An open label randomized multicenter study to assess patient preference for and evaluate clinical benefit of insulin glargine (Lantus) SoloSTAR pen versus conventional...
Sanofi Aventis
A phase 3, multicenter, open-lable, randomized, forced-titration clinical trial evaluating the efficacy and safety of Technosphere® insulin inhalation powder in combin...
MannKind Corporation
The impact of LY2605541 versus insulin glargine for patients with type 2 diabetes mellitus advanced to multiple injection bolus insulin with insulin lispro: a double-b...
Eli Lilly and Company
The impact of LY2605541 versus insulin glargine for patients with type 1 diabetes mellitus treated with preprandial insulin lispro: a double-blind, randomized, 52 week...
Eli Lilly and Company
A prospective, randomized, double-blind comparison of long-acting basal insulin analog LY2963016 to Lantus in adult patients with type 2 diabetes mellitus.
Eli Lilly and Company
A prospective, randomized, double-blind comparison of long-acting basal insulin analog LY2963016 to Lantus in adult patients with type 2 diabetes mellitus.
Eli Lilly and Company
A prospective, randomized, open-lable comparison of a long-acting basal insulin analog LY2963016 to Lantus in combination with mealtime insulin lispro in adult patient...
Eli Lilly and Company
A phase 3, multicenter, double-blind, placebo-controlled, randomized, clinical trial evaluating the efficacy and safety of prandial Technosphere® insulin inhalation po...
MannKind Corporation
Protocol Number CDJN608B2302.
Novartis Pharmaceuticals Corporation
An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease.
Novartis
6-month, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of a new formulation of insulin glargine and Lantus® injected in t...
Sanofi Aventis
6-month, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of a new formulation of insulin glargine and Lantus® in insulin-na...
Sanofi Aventis
A one-year, multi-national, open labeled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin Detemir.
Novo Nordisk Pharmaceuticals, Inc
Phase III multi-center, double-blind, randomized, parallel, group evaluation of the fixed combination Torcetrapib/Atorvastatin, administered orally, once daily.
Pfizer Pharmaceuticals, Inc
A 24-week randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy, safety and tolerability of Tesaglitizar therapy.
AstraZeneca Pharmaceuticals LP
Apidra (insulin Glulisine) administered in a fixed bolus regimen vs. variable bolus regimen based on carbohydrate counting in adult subjects with type 2 diabetes recei...
Aventis Pharmaceuticals, Inc
Safety and efficacy of Exenatide in patients with type 2 diabetes using Thiazolidinediones or Thiazolidinediones and Metformin.
Eli Lilly and Company
A 28-week extension to a mulitcenter, double-blind, randomized, parallel-group study to compare the effect of 24 week treatment with LAF237.
Protocol CLAF2305E1
Join now to see all